Finanzen von Mustang Bio Inc (MBIO)MBIOMustang Bio Inc

Evaluating the bottom line, Mustang Bio Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -58.12%, provide a clear picture of how effectively MBIO converts its operational activities into shareholder value.

In the context of the broader market, MBIO competes directly with industry leaders such as SILO and RDHL. With a market capitalization of $4.50M, it holds a significant position in the sector. When comparing efficiency, MBIO's gross margin of N/A stands against SILO's -14.77% and RDHL's 100.00%. Such benchmarking helps identify whether Mustang Bio Inc is trading at a premium or discount relative to its financial performance.

Mustang Bio has reported continuous losses, with a net income of -$1,072,000 in Q2 2026 and an EPS of -0.16 for the same quarter. The company has a current ratio of 0.00 in Q2 2026, indicating it cannot meet its short-term liabilities.